Condition: Huntington Disease · Sponsor: Western Sydney Local Health District
NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.
This description comes directly from the study's public registry record.
Clement Loy · 001164 4 8890 3560 · clement.loy@sydney.edu.au
Sarah Samperi · 001164 2 8890 9146 · sarah.samperi@health.nsw.gov.au
Always discuss trial participation with your own doctor first.
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| The University of Queensland | Herston, Queensland, Australia | Not Yet Recruiting |
| Calvary Health Care Bethlehem | Parkdale, Victoria, Australia | Not Yet Recruiting |
| The Royal Melbourne Hospital | Parkville, Victoria, Australia | Not Yet Recruiting |
| Perron Institute | Nedlands, Western Australia, Australia | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05509153